Interv Akut Kardiol. 2016;15(3):127-134 | DOI: 10.36290/kar.2016.026

Bioresorbable vascular scaffolds - Magic of the ephemeral?

Vojtěch Novotný, Ivo Varvařovský, Jan Matějka, Vladimír Rozsíval, Tomáš Lazarák
Kardiologické centrum AGEL a.s., Pardubice
Kardiologické oddělení, Pardubická nemocnice

Bioresorbable vascular scaffolds (BVS) represent the most recent substantial change in direction in the field of percutaneous coronary interventions. The idea of temporary scaffolding the vessel and disappearing thereafter is attractive as it can help overcome some of the current metallic drug-eluting stents limitations. The aim of this review article is to situate the technology of BVS in the context of the rapidly evolving domain of coronary interventions, to highlight its potential benefits and pitfalls and to summarize available evidence, both preclinical and clinical. Although many different concepts of BVS are currently in evolution, only those with certificate for clinical use are discussed in detail. This includes technological aspects, implantation techniques and results from existing preclinical studies, randomized trials, registries and meta-analyses.

Keywords: bioresorbable scaffolds, BRS, bioresorbable vascular scaffolds, BVS, Absorb BVS, DEsolve, Magmaris, PCI, DES

Published: October 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotný V, Varvařovský I, Matějka J, Rozsíval V, Lazarák T. Bioresorbable vascular scaffolds - Magic of the ephemeral? Interv Akut Kardiol. 2016;15(3):127-134. doi: 10.36290/kar.2016.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J. 2014; 35(12): 765-776. Go to original source... Go to PubMed...
    2. Ormiston JA, Stewart FM, Roche AH, Webber BJ, Whitlock RM, Webster MW. Late regression of the dilated site after coronary angioplasty: a 5-year quantitativeangiographic study. Circulation 1997; 96: 468-474. Go to original source... Go to PubMed...
    3. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-706. Go to original source... Go to PubMed...
    4. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992; 85: 916-927. Go to original source... Go to PubMed...
    5. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991; 83: 148-161. Go to original source... Go to PubMed...
    6. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991; 324: 13-17. Go to original source... Go to PubMed...
    7. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103: 192-195. Go to original source... Go to PubMed...
    8. Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001; 22: 2125-2130. Go to original source... Go to PubMed...
    9. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780. Go to original source... Go to PubMed...
    10. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441. Go to original source... Go to PubMed...
    11. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202. Go to original source... Go to PubMed...
    12. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391-399. Go to original source... Go to PubMed...
    13. Stone GW, Rizvi A, NewmanW, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674. Go to original source... Go to PubMed...
    14. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378: 1940-1948. Go to original source... Go to PubMed...
    15. Iqbal J, Sumaya W, Tatman V, et al. Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. EuroIntervention 2013; 9: 62-69. Go to original source... Go to PubMed...
    16. Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol 2006; 18: 70-74. Go to PubMed...
    17. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012; 33: 16-25b. Go to original source... Go to PubMed...
    18. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010; 3: 1190-1198. Go to original source... Go to PubMed...
    19. Wentzel JJ, Whelan DM, van der Giessen WJ, et al. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech 2000; 33: 1287-1295. Go to original source... Go to PubMed...
    20. Gyongyosi M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000; 35: 1580-1589. Go to original source... Go to PubMed...
    21. Gomez-Lara J, Brugaletta S, Diletti R, et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 2011; 32: 294-304. Go to original source... Go to PubMed...
    22. Gomez-Lara J, Garcia-Garcia HM, Onuma Y. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010; 3: 1190-1198. Go to original source... Go to PubMed...
    23. Lehoux S, Tedgui A. Cellular mechanics and gene expression in blood vessels. J Biomech 2003; 36: 631-643. Go to original source... Go to PubMed...
    24. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371: 899-907. Go to original source... Go to PubMed...
    25. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58: 1578-1588. Go to original source... Go to PubMed...
    26. Okamura T, Serruys PW, Regar E. Cardiovascular flashlight. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. Eur Heart J 2010; 31: 2179. Go to original source... Go to PubMed...
    27. Eggebrecht H, Rodermann J, Hunold P, et al. Images in cardiovascular medicine. Novel magnetic resonance compatible coronary stent: the absorbable magnesium-alloy stent. Circulation 2005; 112: e303-e304. Go to original source... Go to PubMed...
    28. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910. Go to original source... Go to PubMed...
    29. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 2011; 123: 779-797. Go to original source... Go to PubMed...
    30. van der Giessen WJ, Slager CJ, van Beusekom HM, et al. Development of a polymer endovascular prosthesis and its implantation in porcine arteries. J Interv Cardiol 1992; 5: 175-185. Go to original source... Go to PubMed...
    31. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol. 1998; 32: 780-786. Go to original source... Go to PubMed...
    32. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000; 102: 399-404. Go to original source... Go to PubMed...
    33. Tsuji T, Tamai H, Igaki K, et al. Four-year follow-up of the biodegradable stent (Igaki-Tamai stent). Circ J. 2004; 68: 135.
    34. Onuma Y, Serruys P, Perkins L, et al. Intracoronary optical coherence tomography (OCT) and histology at 1 month, at 2, 3 and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human OCT images in the ABSORB trial. Circulation. 2010; 122: 2288-2300. Go to original source... Go to PubMed...
    35. Ielasi A, Tespili M. Current and future perspectives on drug-eluting bioresorbable coronary scaffolds. Future Cardiol. 2014 May; 10(3): 409-420. Go to original source... Go to PubMed...
    36. Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention. 2009; 5 Suppl F: F58-64. Go to original source... Go to PubMed...
    37. Tenekecioglu E, Farooq V, Bourantas CV, et al. Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovasc Disord. 2016; 16: 38. Go to original source... Go to PubMed...
    38. Testa L, Latib A, Montone RA, Colombo A, Bedogni F. Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease. Circ Cardiovasc Interv. 2016; 9(7). Go to original source... Go to PubMed...
    39. Kimura T, Kozuma K, Tanabe K, et al; ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015; 36: 3332-3342. Go to original source... Go to PubMed...
    40. Lesiak M, Araszkiewicz A. "Leaving nothing behind": is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease? Postepy Kardiol Interwencyjnej. 2014; 10(4): 283-288. Go to original source... Go to PubMed...
    41. Puricel S, Arroyo D, Corpataux N, et al. Comparison of everolimus - and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015; 65: 791-801. Go to original source... Go to PubMed...
    42. Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014; 64(23): 2541-2551. Go to original source... Go to PubMed...
    43. Giacchi G, Ortega-Paz L, Brugaletta S, Ishida K, Sabaté M. Bioresorbable vascular scaffolds technology: current use and future developments. Med Devices (Auckl). 2016; 9: 185-198. Go to original source... Go to PubMed...
    44. Everaert B, Felix C, Koolen J, et al. Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users: a position statement on the use of bioresorbable vascular scaffolds in the Netherlands. Neth Heart J. 2015; 23: 161-165. Go to original source... Go to PubMed...
    45. Rzeszutko L, Depukat R, Dudek D. Biodegradable vascular scaffold ABSORB BVS(TM) - scientific evidence and methods of implantation. Postepy Kardiol Interwencyjnej. 2013; 9(1): 22-30. Go to original source... Go to PubMed...
    46. Miyazaki T, Latib A, Ruparelia N, et al. The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: a comparison with conventional balloon predilatation. EuroIntervention. 2016; 11(14): e1580-e1588. Go to original source... Go to PubMed...
    47. Urgentní bezpečnostní oznámení pro terén/doporučení pro lékaře, 27. července 2016, Abbott Vascular
    48. Abellas-Sequeiros RA, Ocaranza-Sanchez R, Galv?o Braga C, et al. Assessment of effectiveness and security in high pressure postdilatation of bioresorbable vascular scaffolds during percutaneous coronary intervention. Study in a contemporary, non-selected cohort of Spanish patients. Int J Cardiol. 2016; 219: 264-270. Go to original source... Go to PubMed...
    49. Ormiston JA, Webber B, Ubod B, Webster MW, White J. Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies. EuroIntervention. 2015; 10(10): 1169-1177. Go to original source... Go to PubMed...
    50. Lu C, Filion KB, Eisenberg MJ. The safety and efficacy of absorb bioresorbable vascular scaffold: a systematic review. Clin Cardiol. 2016; 39: 48-55. Go to original source... Go to PubMed...
    51. Lipinski MJ, Escarcega RO, Baker NC, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2016; 9: 12-24. Go to original source... Go to PubMed...
    52. Cutlip DE, Windecker S, Mehran R, et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17): 2344-2351. Go to original source... Go to PubMed...
    53. Serruys PW, Ormiston J, van Geuns RJ, et al. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J Am Coll Cardiol. 2016; 67: 766-776. Go to original source... Go to PubMed...
    54. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. Euro Intervention. 2015; 10: 1144-1153. Go to original source... Go to PubMed...
    55. Internetová stránka EuroPCR Congress 2015. Data dostupná na: http://www.pcronline.com/Lectures/2015/Ghost-EU-update. Zobrazeno 22. srpna 2016.
    56. Kočka V, Malý M, Toušek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Eur Heart J. 2014; 35: 787-794. Go to original source... Go to PubMed...
    57. Cortese B, Ielasi A, Romagnoli E, et al. Clinical comparison with shortterm follow-up of bioresorbable vascular scaffold versus everolimuseluting stent in primary percutaneous coronary interventions. Am J Cardiol. 2015; 116: 705-710. Go to original source... Go to PubMed...
    58. Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014; 9: 1036-1041. Go to original source... Go to PubMed...
    59. Wiebe J, Möllmann H, Most A, et al. Short-term outcome of patients with ST segment elevation myocardial infarction (STEMI) treated with an everolimuseluting bioresorbable vascular scaffold. Clin Res Cardiol. 2014; 103: 141-148. Go to original source... Go to PubMed...
    60. Wöhrle J, Naber C, Schmitz T, et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. Euro-Intervention. 2015; 11: 149-156. Go to original source... Go to PubMed...
    61. Costopoulos C, Crowson MC, Brown AJ, et al. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold implantation in a real-world population: A single-center experience. Cardiovasc Revasc Med. 2015; 16: 461-464. Go to original source... Go to PubMed...
    62. Robaei D, Back L, Ooi SY, Pitney M, Jepson N. Twelve-month outcomes with a bioresorbable everolimus-eluting scaffold: results of the ESHCBVS registry at two Australian centers. J Invasive Cardiol. 2016; 28(8): 316-322. Go to PubMed...
    63. Costopoulos C, Latib A, Naganuma T, et al. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc Interv. 2015; 85: e10-e15. Go to original source... Go to PubMed...
    64. Sato K, Latib A, Panoulas VF, et al. Procedural feasibility and clinical outcomes in propensity-matched patients treated with bioresorbable scaffolds vs new-generation drug-eluting stents. Can J Cardiol. 2015; 31: 328-334. Go to original source... Go to PubMed...
    65. Muramatsu T, Onuma Y, van Geuns RJ, et al. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials. JACC Cardiovasc Interv. 2014; 7: 482-493. Go to original source... Go to PubMed...
    66. Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv. 2015; 8: 189-197. Go to original source... Go to PubMed...
    67. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015; 385: 43-54. Go to original source... Go to PubMed...
    68. Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015; 373: 1905-1915. Go to original source... Go to PubMed...
    69. Kereiakes D. Absorb III Study. Prezentováno na: Transcatheter Cardiovascular Therapeutics 2015, 12. října 2015, San Francisco, USA.
    70. Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015; 36: 3332-3342. Go to original source... Go to PubMed...
    71. Gao R, Yang Y, Han Y, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. J Am Coll Cardiol. 2015; 66: 2298-2309. Go to original source... Go to PubMed...
    72. Puricel S, Arroyo D, Corpataux N, et al. Comparison of everolimus - and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015; 65: 791-801. Go to original source... Go to PubMed...
    73. Sabaté M, Windecker S, I?iguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016; 37: 229-240. Go to original source... Go to PubMed...
    74. Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patientlevel, pooled meta-analysis. Lancet. 2016; 387(10025): 1277-1289. Go to original source... Go to PubMed...
    75. Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016; 387(10018): 537-544. Go to original source... Go to PubMed...
    76. Bangalore S, Toklu B, Bhatt DL. Outcomes with bioabsorbable vascular scaffolds versus everolimus eluting stents: Insights from randomized trials. Int J Cardiol 2016; 212: 214-222. Go to original source... Go to PubMed...
    77. Kang SH, Chae I, Park J, et al. Stent Thrombosis with Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence from a Network Meta-Analysis of 147 Trials. JACC: Cardiovasc Interv 2016; 9: 1203-1212. Go to original source... Go to PubMed...
    78. Capodanno D. Overlapping metaanalyses of bioresorbable vascular scaffolds versus everolimus eluting stents: bringing clarity or confusion? J Thorac Dis 2016; 8(7): 1366-1370. Go to original source... Go to PubMed...
    79. Giacchi G, Ortega-Paz L, Brugaletta S, Ishida K, Sabaté M. Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks. Postepy Kardiol Interwencyjnej. 2015; 11: 161-169. Go to original source... Go to PubMed...
    80. Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6 - and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014; 7: 89-99. Go to original source... Go to PubMed...
    81. Abizaid A, Costa RA, Schofer J, et al. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions. JACC Cardiovasc Interv. 2016 Mar 28; 9(6): 565-574. Go to original source... Go to PubMed...
    82. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007; 369: 1869-1875. Go to original source... Go to PubMed...
    83. Haude M, Erbel R, Erne P. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Euro Intervention. 2016; 12(2): e160-e166. Go to original source... Go to PubMed...
    84. Waksman R, Pakala R, Kuchulakanti PK, et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv. 2006; 68: 607-617. Go to original source... Go to PubMed...
    85. Haude M, Ince H, Abizaid A, et al. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. Eur Heart J. 2016 May 17. Go to original source... Go to PubMed...
    86. Džavík V, Colombo A. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing. JACC Cardiovasc Interv. 2014 Jan; 7(1): 81-88. Go to original source... Go to PubMed...
    87. Capranzano P, Gargiulo G, Capodanno D, et al. Treatment of coronary bifurcation lesions with bioresorbable vascular scaffolds. Minerva Cardioangiol. 2014 Jun; 62(3): 229-234. Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.